Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study
Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …
[HTML][HTML] Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort …
M Grymonprez, TL De Backer, X Bertels… - Frontiers in …, 2023 - frontiersin.org
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …
Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the …
WL Baker, MS Roberts, Y Bessada… - Current Medical …, 2023 - Taylor & Francis
Background Advancing age is a risk factor for developing non-valvular atrial fibrillation
(NVAF) or acute venous thromboembolism (VTE). We assessed the comparative …
(NVAF) or acute venous thromboembolism (VTE). We assessed the comparative …
Benefits and Harms of Standard Versus Reduced‐Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation
Background Dose reduction of direct oral anticoagulant (DOAC) medications is
inconsistently applied to older adults with multiple morbidities, potentially due to perceived …
inconsistently applied to older adults with multiple morbidities, potentially due to perceived …
COVID-19 pandemic and initiation of treatment for atrial fibrillation: a nationwide analysis of claims data
Background The COVID-19 pandemic profoundly disrupted the delivery of medical care. It
remains unclear whether individuals diagnosed with new onset disease during the …
remains unclear whether individuals diagnosed with new onset disease during the …
Utilization outcomes of direct oral anticoagulants in Medicare patients
P Arora, M Muehrcke, M Russell, S Ghanekar - Research in Social and …, 2023 - Elsevier
Objective To compare the adherence, persistence, discontinuation and switching rates of
direct oral anticoagulants (DOACs) for Medicare patients with non-valvular atrial fibrillation …
direct oral anticoagulants (DOACs) for Medicare patients with non-valvular atrial fibrillation …
[PDF][PDF] Association between genetic polymorphisms in fibrinogen genes and bleeding risk in patients treated with direct oral anticoagulants
Introduction: This study aimed to investigate the association between polymorphisms in
fibrinogen genes and bleeding risk in patients receiving direct oral anticoagulants (DOACs) …
fibrinogen genes and bleeding risk in patients receiving direct oral anticoagulants (DOACs) …
Risk of thromboembolic events in relation to the management of anticoagulant and antiagregant therapy in patients subjected to endoscopic retrograde …
RM Alejandre-Altamirano, J Castro-Rodríguez… - … y Hepatología (English …, 2023 - Elsevier
Background and objectives The main clinical practice guidelines recommend adequate
periprocedural withdrawal and reintroduction of antithrombotic drugs in case of invasive …
periprocedural withdrawal and reintroduction of antithrombotic drugs in case of invasive …
Riesgo de eventos tromboembólicos en función del manejo de la terapia anticoagulante y antiagregante en pacientes sometidos a colangiopancreatografía …
RM Alejandre-Altamirano, J Castro-Rodríguez… - Gastroenterología y …, 2023 - Elsevier
Antecedentes y objetivos Las principales guías de práctica clínica recomiendan un
adecuado manejo periprocedimiento de los fármacos antitrombóticos en caso de …
adecuado manejo periprocedimiento de los fármacos antitrombóticos en caso de …
Comparison of the efficacy and risk of therapy with the vitamin K antagonist Phenprocoumon with new oral anticoagulants in catheter ablation of atrial fibrillation
D Gjermeni - 2023 - tobias-lib.ub.uni-tuebingen.de
Introduction The use of novel oral anticoagulants (NOAC) in patients undergoing catheter
ablation of atrial fibrillation (AF) is as effective and safe as standard Warfarin therapy …
ablation of atrial fibrillation (AF) is as effective and safe as standard Warfarin therapy …